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Gastrointestinal stromal tumor (GIST) is a nonepithelial, mesenchymal tumor ﬁrst described by Mazur and Clark in 1983. Since
then, its molecular biology has been studied in great detail. Special interest in the role of tyrosine kinase in its regulation has been
thetargetbydiﬀerentdrugresearch.Mutationinc-kit exons9,11,13,17andPDGFRAmutationinexons12,14,18areresponsible
for activation of gene signaling system resulting in uncontrolled phosphorylation and tissue growth. However, 5 to 15% of GISTs
does not harbor these mutations, which raises additional questions in another alternate signaling pathway mutation yet to be
discovered. Diagnosis of GISTs relies heavily on KIT/CD117 immunohistochemical staining, which can detect most GISTs except
forafew3%to5%thatharborsPDGFRAmutation.NewerstainingagainstPKCthetaandDOG-1genesshowedpromisingresults
butarenotreadilyavailable. ClinicalmanifestationofGISTsisbroadandhighlydependentontumorsize.Surgerystillremainsthe
ﬁrst-line treatment for GISTs. The advancement of molecular biology has revolutionized the availability of newer drugs, Imatinib
andSunitinib.TogetherwithitsadvancementistheoccurrenceofImatinib/Sunitinibdrugresistance.Withthis,newermonoclonal
antibody drugs are being developed and are undergoing clinical trials to hopefully improve survival in patients with GISTs.
1.Introduction
Gastrointestinal stromal tumor (GIST) has an estimated an-
nualincidenceintheUSofapproximately3,000–4,000,mak-
ing it the most common primary mesenchymal tumors of
the gastrointestinal tract [1, 2]. GISTs are thought to arise
from interstitial cells of Cajal (ICC) or their stem cell pre-
cursors which are normally part of the autonomic nervous
system of the intestine [2, 3]. ICC serves as a pacemaker
function in controlling motility. GISTs usually arise in the
stomach in 40% to 70%, in the small intestine in 20% to
40%, and less than 10% in the esophagus, colon, and rectum
[3–6]. GISTs can develop outside the intestinal tract, within
the abdominopelvic cavity such as the omentum, mesentery,
uterus, and the retroperitoneum; they are called extragastro-
intestinal stromal tumors (eGIST), usually behaving aggres-
sively [2, 4, 7, 8]. GIST has been shown to aﬀect men (55%)
more than women with median age of 55–60 [9].
In 1941, Golden and Stout described a set of mesenchy-
mal tumors arising in the bowels which were mistakenly
identiﬁed as tumors arising from the smooth muscle’s cells
as leiomyoblastoma, leiomyoma, and leiomyosarcoma [2].
Although the term “GIST” was ﬁrst used in 1983 by Mazur
andClark,itwasin1998whenJapaneseresearchersdiscover-
ed the presence of a KIT protein and the possibility of kit
mutations, which distinguishes GISTs from other similar
tumors. Prior to that time, KIT testing by immunohisto-
chemistry was not readily available and GIST was not always
clearly recognized as a distinct sarcoma type [2].
Since the discovery of KIT protein, its expression in GIST
h a sb e e nag r e a ta r e ao fm o l e c u l a rb i o l o g i cr e s e a r c h .I tr e -
volutionized its pathophysiology and relationship in the
development of stromal tumors. Estimated 85% of GIST tu-
m o r sw e r ef o u n dt oh a v ea na c t i v em u t a t i o ni nt h ekit proto-
oncogene while only 3–5% mutation in PDGFRA [1].
For many years, the mainstay of treatment for GIST is
surgical resection. Unfortunately, the results of surgery alone
have been inadequate, with up to 50% of patients develop-
ing tumor recurrence within the ﬁrst ﬁve years [1]. Postoper-
ative chemotherapy with conventional agents and radiation2 ISRN Gastroenterology
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Figure 1: Schematic representation of KIT and platelet-derived growth factor receptor alpha (PDGFRA) molecule with location and
frequency of mutation.
therapy were ineﬀective as well [1, 4]. With the recent advan-
cement of proto-oncogene testing and immunohistochem-
ical staining, treatment for GIST has evolved with thera-
pies directed against speciﬁc kit/PDGFRA proto-oncogene,
showing promising results. The use of small-molecule kinase
inhibitors that target the underlying pathogenic mutant
kinase has revolutionized the treatment of GIST. However,
recently reported cases are showing emergence of drug-
resistant tumor clones, which limit the long-term beneﬁts of
these drugs [10].
This paper will summarize recent case reports, progress
in the diagnosis and treatment of GIST, and how to ap-
proach patients with GIST as well as future directions in
management of GISTs. The selection of case report was done
at random, based on keywords “case reports in GIST,” “gas-
trointestinal stromal tumors case reports,” “extraintestinal
GIST,” and “eGIST” using the search engine of pubmed,
googlescholar,andthedirectoryofopenaccessjournals.The
cases presented are only a representative of the numerous
case reports regarding GISTs.
2.MolecularBiology
2.1. c-kit. GISTs are mesenchymal tumors of the gastroin-
testinal tract characterized by their genetic expression of kit
and immunohistochemical staining of CD117, which occurs
in 85% to 95% of all GISTs [2, 10]. kit is a 145kD trans-
membranetyrosinekinasewhichservesasareceptorforstem
cellfactor[10].Thebindingofstemcellreceptortokit results
in homodimerization of its receptor with the activation of
tyrosine kinase and concomitant activation of downstream
intracellular signal transduction pathways, most notably
RAS-RAF-MAPK and P13K-AKT-mTOR pathways [10].
This results in modiﬁcation of several cellular functions,
which includes adhesion, migration, diﬀerentiation, and
cellular proliferation with decrease in cellular apoptosis.
These oncogenic potentials would ultimately lead to neo-
plasia [2]. The mutation of the kit proto-oncogene tends to
cluster in four exons, namely, exon 9 (extracellular domain),
exon 11 (intracellular juxtamembrane domain), exon 13
(split kinase domain), and exon 17 (kinase activation loop),
(Figure 1)[ 2, 3].
Exon 11 mutations, which encode for juxtamembrane
domain, are the most common mutated regions of kit. They
account for 70% of all the tumors and do not appear to be
associatedwithanyspeciﬁclocation,size,orclinicaloutcome
[2].In-framedeletionsof1ormorecodonsinexon11kit are
the most common mutations, accounting for 60% to 70%.
The majority of these mutations involves the proximal part
of kit exon 11 between codons Gln550 and Glu561 [3, 11].
Deletion of Trp557 and Lys558 in exon 11 codon, which is
the most common simple deletion in GISTs, is associated
withpoorerclinicaloutcomewithmoreaggressivemetastatic
behavior [3, 12].
Missense point mutation in kit exon 11 is the next most
common type of mutation, occurring in 20% to 30% of
GISTs. They involve almost exclusively three codons, Trp557,
Val559, and Val560, in the proximal part, and Leu576 in the
distal part of exon 11. GIST with missense mutation at these
regions seems to have better prognosis in gastric but not in
small intestinal tumors [3].
Exon 9 mutations are the second most often involved
region which entails mutations of the extracellular domain
[3, 10]. These account for 10% of tumors and are most com-
monlyassociated withGISTof thesmallbowel witha known
aggressive clinical behavior [2, 3]. Nearly all mutations in
exon 9 have been identical with 6-nucleotide duplications,
encoding Ala502-Tyr503, this was initially reported by
Miettinen and Lasota [3], Lux et al. [13].ISRN Gastroenterology 3
Primary mutation of exon 13 (split kinase domain) and
exon 17 (loop) are rare, accounting for <1% of the cases.
Exon13involvesmissensemutationsresultinginsubstitution
of Glu for Lys with a more malignant potential [3].
2.2. PDGFR Alpha. A closely homologous tyrosine kinase
PDGFRA is seen in 5% to 7% of GISTs. They harbor muta-
tionsindecreasingorderoffrequency,involvingexons12,14,
and 18 (Figure 1)[ 3, 14–16]. kit and PDGFRA are mutually
exclusive, and like c-kit they activate similar transduction
pathwaysthatsupportGISToncogenesisbutactatadiﬀerent
receptor site. Most PDGFRA mutant GISTs are located in
the stomach, behaving aggressively. They have an epithelioid
morphology with weak or negative immunohistochemical
reaction to CD117 [2]. A case report by Todoroki et al.
reports a PDGFRA mutation at exon 12, located at the
greateromentumofthestomachwithimmunohistochemical
staining that is weakly positive for CD117, showing an
epithelioid morphology (Table 1). The patient responded to
Imatinib treatment with no recurrence after six months.
More than 80% of PDGFRA mutations occur in exon 18.
They are mostly missense mutations leading to substitution
of Asp to Val. These tumors are usually resistant to treatment
with imatinib [3]. Missense mutation aﬀecting exon 14 has
also been reported with substitution of Asn to Lys or Tyr.
These tumors have better prognosis than the earlier [3, 16].
On the other hand, mutations of exon 12 are extremely rare
[3].
2.3. Wild Type. 5% to 15% of GISTs do not harbor either
kit or PDGFRA mutations and are known as wild-type
GISTs [2, 5] .T h e s et u m o r sc a nb ep o s i t i v ef o rC D 1 1 7a n d
can be mistakenly labeled as an Imitanib-susceptible GIST
[2, 9]. However, these tumors are considered less respon-
sive to imatinib treatment with a poorer prognosis. It has
been suggested that these tumors harbor the insulin growth
factor 1 receptor (IGF1R) mutation, which is highly express-
ed in both adult and pediatric wild-type GIST. The down-
regulation of IGF1R activity would lead to cytotoxicity or
induced apoptosis in experimental studies [5].
3.ClinicalFeatures
The spectrum of clinical presentation in GIST is broad. It is
largely dependent on tumor size and location. GIST-caus-
ing symptoms are usually larger in size, more than 6cm in
diameter [9]. The most common presentation of GIST is
abdominal pain and/or GI bleeding [2, 42]. This may be
acute,asinmelena,hematemesis,orchronicinsidiousbleed-
ing leading to anemia [2]. GIST can also cause symptoms
secondary to mass eﬀect, including satiety, bloating, and
abdominal pain [2, 9]. In our case review, abdominal pain
is the most common complaint, followed by mass eﬀects and
GI bleed. Other symptoms observed in our review include
pelvicpain,pleuritic chestpain, smallbowelobstruction,dy-
suria, altered bowel movement, nausea, and weight loss
(Table 1).
About 70% of patients with GISTs develop symptoms;
the remaining 20% to 30% are diagnosed incidentally or at
autopsy [2, 9]. These ﬁndings correlate closely with our ob-
servation that 5 out of 32 (15%) case reports on GISTs
were found incidentally [7, 20, 22, 27, 37]. Approximately
20% to 25% of gastric and 40% to 50% of small intestinal
GISTsareclinicallymalignant.Themostcommonmetastatic
sites include the abdominal cavity, liver, and rarely bones
and soft tissues. GISTs very rarely, if not, metastasize to the
lymph nodes and the skin [9, 43]. In the case reports that
we reviewed, abdominal cavity was the most common meta-
static site followed by the liver and the pancreas. No lymph
node metastases were noted (Table 1).
3.1. Familial GISTs and GISTs Syndromes. Less than 5% of
GISTs can be associated with one of the four tumor syn-
dromes: familial GISTs, neuroﬁbromatosis type 1 (NF1),
Carney’s triad (CT), and, recently, the Carney-Stratakis triad
(CSS) [4, 44–46].
Familial GIST syndrome (FGS) has been reported and
identiﬁed in diﬀerent families worldwide. FGS is inherited
as autosomal dominant pattern harboring multiple, some-
times diﬀuse GISTs. Clinical presentation of FGS includes
hyperpigmentation, increase in the number of nevi, urticaria
pigmentosa, and/or systemic mastocytosis [4, 44]. Dyspha-
gia,whichisphysiologicallydiﬀerentfromtrueachalasia,has
been reported in family members aﬀected by FGS. Familial
GIST syndrome usually presents with multiple GIST in the
small bowel and to a lesser extent, in the stomach. It has also
been described in the esophagus and the rectum [44]. Mor-
phologically, these tumors are indistinguishable from spo-
radic GISTs and are characterized with low mitotic rates.
Most of FGS also expresses CD117/KIT, as well as CD34 in
immunohistochemical staining [4, 44].
Neuroﬁbromatosis type I (NF1) can also harbor multiple
GISTsinapproximately7%ofpatients.Thisresultsfromger-
mline mutation of NF-1 gene that encodes neuroﬁbromin.
They are often diagnosed in the late ﬁfth and sixth decades
of life with slight female predominance [4, 44]. The most
characteristicﬁndingsofNF-1include caf´ eaulaitspots,axil-
lary and inguinal freckling, multiple dermal neuroﬁbromas,
and Lisch nodules. Although gastrointestinal manifestations
of NF-1 are less frequent than cutaneous manifestation, it is
notuncommon.Thesesymptomsincludehyperplasticlesion
of intestinal neural tissue, GISTs, endocrine cell tumor of
duodenum, and the periampullary region, as well as other
miscellaneous groups of tumors [47].
ClinicalfeaturesofNF-1-associatedGISTaremoreclose-
ly similar to CT than to CSS [44]. NF-1-related GISTs are
usually multiple, occurring in the small bowel, exhibit a
spindle-shaped morphology, and do not harbor either kit or
PDGFRA mutations, although it can express KIT in immu-
nohistochemicalstaining[4].Itisbelievedthatthedeﬁciency
of neuroﬁbromin promotes the growth of speciﬁc subtype of
I C Ci nc o n t r a s tt od i r e c tm u t a t i o no ft h ekit signaling system
seen in non-NF-1-GISTs [47]. Most cases of NF1-associated
GIST have an indolent course, but some were mitotically
active and were clinically malignant [48].
The carney triad (CT) and the more recent Carney-
Stratakis syndrome (CSS) are the two other syndromes that
predispose to GISTs. CT was ﬁrst described by Carney and4 ISRN Gastroenterology
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colleagues in 1977. CT generally occurs in females at a
younger age, typically before the age of 30, presenting with
a combination of multiple gastric GIST, paraganglioma, and
pulmonary chondroma [4, 44–46, 49]. These lesions tend
to have higher risks of metastasis, particularly to the lymph
nodes. They are morphologically diﬀerent from sporadic
GISTs. No germ-line mutation speciﬁc for CT has been dis-
covered to date. Neither kit nor PDGFA proto-oncogene has
been found on analysis of these patients [4, 44].
CSS occurs at a younger age group than that of CT,
with mean age of 23 years old. Both males and females are
equally aﬀected [44]. CSS-related GISTs tend to be multiple,
localized in the stomach, with an epithelioid morphology
on biopsy. Clinically, these patients present with multifocal
GISTs, paragangliomas, and pheochromocytomas. Carney
Stratakis syndrome GISTs occur because of germline muta-
tions in the enzyme succinate dehydrogenase (SDH) [4, 49].
In our review, four cases of NF-1-associated GIST were re-
corded (Table 1)[ 22, 37, 39, 40].
4.Pathologic Features
GISTs normally present a wide clinical-pathological spec-
trum, from a small incidental nodule to large pedunculated
mass. They are usually described as a tan to white, well-
circumscribed lesions within the walls of the stomach [4].
GISTs demonstrate either of the 3 main histologic cell types:
spindle cell type (most common), epithelioid cell type, and
the mixed spindle-epithelioid type [3–5, 9].
Spindle cell GISTs account for 70% of the tumors [48].
The same is the most commonly reported histological pat-
tern on our review (Table 1). Histologic subtypes for spind-
le cell GISTs include sclerosing spindle-cell, palisading-va-
cuolated subtype, hypercellular subtype, and sarcomatous
spindle cell [48].
Epithelioid cell’s type accounts for the next 20% with the
remaining showing mixed pattern. Epithelioid histological
subtypes include sclerosing epithelioid variant, dyscohe-
sive epithelioid, hypercellular epithelioid, and sarcomatous
epithelioid GISTs. Epithelioid morphology is closely related
toPDGFRAmutationwithamoreaggressivetumorbehavior
[48]. Todoroki et al. reported an epithelioid histological pat-
tern in a GIST with PDGFRA mutation (Table 1)[ 34].
5. Immunohistochemical Staining
5.1. CD117/KIT. Greater than 95% of GISTs are positive
for CD117/KIT but are no longer considered as an absolute
requirement [3–5]. Commonly expressed but less GISTs-
speciﬁc antigens are CD34, nestin, smooth muscle actin
(SMA), caldesmon, calponin, vimentin, and embryonic
smooth muscle myosin. GISTs are generally negative or are
weakly positive for desmin. S100 positivity is rare but rela-
tively more common in small intestinal GISTs than gastric
GISTs [3, 4]. Tumors that can consistently test positive for
KIT include mastocytoma, seminoma, pulmonary small cell
carcinoma, and extramedullary myeloid tumors. Abdominal
or GI tumors that may test positive for KIT are metastat-
ic melanoma, clear-cell sarcoma (30% to 50%), Ewing’s
sarcoma (50%), childhood neuroblastoma (30%), angiosar-
coma (50%), and some carcinoma [3].
5.2. CD34. CD34 is positive in 80% to 85% of gastric GISTs
andabout50%insmallintestinalGISTs.Thespindlevariants
are more likely to stain with CD34 than the epithelioid
variants. Sarcomatous variants have higher tendency to stain
withCD34thanthenonsarcomatoushistologicsubtype[48].
Out of the 32 case reports reviewed, all were positive for
CD117/KIT. One of these was weakly reactive to CD117/KIT
that is related to PDGFRA mutation [34]; and another re-
lated to wild-type mutation [39]. 19 of these cases with
spindle-shaped morphology were concomitantly positive for
CD34. Other immune markers noted in the review include
SMA, S-100, neuron-speciﬁc enolase (NSE) (Table 1).
5.3. Protein Kinase C Theta. Protein kinase C theta is a
novelproteinkinase,downstreameﬀectorinthekit signaling
system that is involved in T-cell activation, signal trans-
duction, and neuronal diﬀerentiation [48, 50, 51]. Various
studies have shown that PKC theta is strongly expressed
and is overexpressed in GISTs, but not in other sarcomas
[51–53]. These studies established PKC theta as a diagnostic
marker for GIST. Studies have also suggested that the loss
of PKC theta expression could be responsible for inhibition
of kit expression in GISTs, hence does not react to KIT
staining [51]. In study conducted by kim et al. on 220 GIST
tumors, 212 were positive to PKC theta (96%) while KIT
was positive in 216 (98%). However, two samples that are
PKC theta positive and KIT negative showed mutation in
PDGFRA,indicatingthatPKCthetamightbeausefulmarker
in diagnosing KIT-negative PDGFRA mutation tumors [50].
Although, other investigators believe that PKC theta staining
is often weak and less distinct than CD117/KIT staining [4].
5.4. DOG1. Discovered on GIST-1 (DOG-1) is a novel gene
encoding for a hypothetical protein that has been ubiqui-
tously expressed on GISTs [54, 55]. In a study conducted
by West et al., immunoreactivity for DOG1 GIST samples
was 97.8% reactive. They have demonstrated a reaction to
DOG1 on tissues that express PDGFRA mutation that failed
to react for KIT immunostaining. These tests were later
conﬁrmed with in situ hybridization for DOG1, kit, and
PDGFRAmutation.DOG1ishighlyexpressednotonlyinty-
pical GISTs but also in kit-mutation-negative GISTs [55].
Another study, conducted by Espinosa et al. on DOG1
antibody, showed a high sensitivity and speciﬁcity, with 87%
immunoreaction to GISTs. In contrary, only 74% reacted
to CD117/KIT immunostaining [54]. Since 5 to 7% of
P D G F R AG I S T sm u t a t i o na n d5 %o fkit-mutated GISTs
do not react to CD117/KIT, DOG-1 staining would be an
essential tool for a more reliable diagnosis on GISTs [54,
55]. Moreover, PDGFRA GISTs mutation can still beneﬁt
from imatinib treatment, making DOG-1 an important tool
in these conditions. DOG1 immunohistochemistry staining
is commercially available in some countries, including the
United States under the trade name Thermo Scientiﬁc,
GenWay Biotech, LSBio, and Leica.ISRN Gastroenterology 9
Table 2: AFIP-Miettinen risk stratiﬁcation system.
Risk stratiﬁcation of primary GIST by mitotic index, size, and site∗
Tumor parameters Risk of progressive disease∗ (%)
Mitotic index Size Gastric Duodenum Jejunum/ileum Rectum
≤5 per 50hpf
≤2cm ∗∗ None (0%) None (0%) None (0%) None (0%)
>2 ≤ 5cm Very low (1.9%) Low (4.3%) Low (8.3%) Low (8.5%)
>5 ≤ 10cm Low (3.6%) Moderate (24%) (Insuﬀ. data) (Insuﬀ. data)
>10cm Moderate (10%) High (52%) High (34%) High (57%)
≤2cm None † High† (Insuﬀ. data) High (54%)
>5 per 50hpf >2cm≤ 5cm Moderate (16%) High (73%) High (50%) High (52%)
>5cm≤ 10cm High (55%) High (85%) (Insuﬀ. data) (Insuﬀ. data)
>10cm High (86%) High (90%) High (86%) High (71%)
These Data are based on long-term followup of 1055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal GISTs.
Abbreviations: GIST—gastrointestinal stromal tumor;hpf—high power ﬁeld. Insuﬀ—insuﬃcient.
∗Deﬁned as metastasis or tumor-related death.
†Denotes small numbers of cases.
Adapted from Miettinen and Lasota, 2006 with permission from Elsevier [48].
6. Risk Assessment inGIST
Tumor size, location, and mitotic index remain the main
variables used in risk stratiﬁcation systems ﬁrst developed by
the National Institute of health, the so-called Fletcher’s cri-
teria [4, 5]. Revised version of the NIH risk stratiﬁcation
system by inclusion of additional prognostic factors, such as
nonradical resection (R1) and a tumor rupture that aﬀects
adverse outcomes, was proposed by several investigators; and
was later referred to as the modiﬁed NIH criteria [56, 57].
Tumor location was subsequently shown to have indepen-
dent prognostic value and was later incorporated into the
Miettinen-Lasota/Armed Forces Institute of Pathology risk
stratiﬁcation system (AFIP) (Table 2)[ 58]. The AFIP system
has the advantage of delivering numerically calculated risk
of tumor relapse and/or progression, which is a vital tool in
helping clinicians make solid therapeutic decisions [3, 56].
The guidelines have also been recommended by both the
National Comprehensive Cancer Network (NCCN) and the
College of American Pathologist (Table 2)[ 4]. The same
guidelines were equally used by most of the case reports we
have reviewed (Table 1). The major drawback of the AFIP
system is its complexity, considering eight prognostic sub-
groups and further subdivision into diﬀerent subgroups.
This reduces the prognosis sensitivity and speciﬁcity of re-
currence [56].
On the other hand, the NIH system has the tendency
to overgrade gastric tumors and downgrade a subset of
nongastric tumors as compared to the AFIP system [56]. The
complexity of AFIP risk stratiﬁcation led to the proposal of
a TNM classiﬁcation system for GISTs. The seventh edition
of the international union against cancer (UICC) published
on 2010 included, for the ﬁrst time, a classiﬁcation and
staging system for GIST using the TNM system (Table 3,
TNM system 2010) [59]. The principal aim of the TNM
system is to facilitate a uniform and standardized analysis of
malignant tumors based on their stage of development and
degree of spread. Other investigators argued that using TNM
system is no more than renaming the existing risk group that
was developed by AFIP [56]. Whether TNM system is better
thanthecurrentAFIPsysteminriskstratiﬁcationneedstobe
further validated. None of the case reports we reviewed used
the TNM system as a method of stratiﬁcation (Table 1).
A recent population-based observational cohort study
involving 2560 patients by Joensuu et al. compared the NIH
criteria, the modiﬁed NIH criteria and the AFIP system for
risk stratiﬁcation for recurrence-free survival (RFS) in ima-
tinib naive operable GISTs. Data from the study suggested
that large tumor size, high mitotic count, nongastric loca-
tion, presence of rupture, and male sex were the independent
prognostic factors for RFS. The three criteria in the study
did fairly accurate in estimating RFS with the modiﬁed NIH
criteria, able to identify a single high-risk group. The group
further concluded that most operable GISTs are cured with
surgery alone in about 60% of cases, considering 15 years of
RFS (95% CI, 56.2–63.6) and thus does not beneﬁt from sys-
temic adjuvant therapy [60]. The TNM system of risk strati-
ﬁcation suggested by UICC was not included in this study.
7. Treatment
7.1. Surgery. Despite the impressive advances in targeted
therapy, surgery resection with preservation of the pseudo-
capsule remains the primary mode of therapy for localized
GISTs [4, 5, 61, 62]. Surgery is used in three main approach-
es, most commonly as an initial treatment (primary surgery)
after diagnosis, especially if the tumor is solitary and can be
easily removed. It can be used after neoadjuvant treatment
to shrink the size of the tumor; and, in some cases, surgery
is used for advanced metastatic disease for symptomatic
relief, termed debulking surgery [62]. These tumors should
be handled carefully to avoid tumor rupture and spread.
Lymphadenectomy is not routinely recommended since
GISTs, as mentioned before, rarely metastasize to the lymph
nodes. GISTs respond poorly to conventional chemotherapy
and radiation therapy [4].
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Table 3: The new TNM risk stratiﬁcation system [59].
TNM classiﬁcation for gastric GIST including primary, solitary
omental GISTs
Stage T N M Mitotic rate per 50hpf
Stage IA T1,T2 N0 M0 <5
Stage IB T3 N0 M0 <5
Stage II T1, T2 N0 M0 >5
T4 N0 M0 <5
Stage IIIA T3 N0 M0 >5
Stage IIIB T4 N0 M0 >5
Stage IV Any T N1/Any N M0/M1 Any rate
TNM classiﬁcation for small intestinal GIST including esophagus,
colon, rectum, mesentery, and other less common sites
Stage T N M Mitotic rate per 50hpf
Stage IA T1,T2 N0 M0 <5
Stage II T3 N0 M0 <5
Stage IIIA T1 N0 M0 >5
T4 N0 M0 <5
Stage IIIBT2, T3, T4 N0 M0 >5
Stage IV Any T N1/any N M0/M1 Any rate
T-primary tumor
TX cannot be assessed
T0 no evidence of primary tumor
T1 Tumor ≤2cm
T2 Tumor >2cmto5cm
T3 Tumor >5cmto10cm
T4 Tumor >10cm
N-regional lymph node
NX cannot be assessed
N0 No lymph node involvement
N1 Lymph node involvement
M-distant metastasis
M0 No distant metastasis
M1 Distant metastasis
metastatic lesion by Dickhoﬀ et al. did not receive surgical
intervention; instead patient received Imatinib treatment
with tumor regression on followup. This is in accordance
with the NCCN guidelines for treatment of metastatic tumor
(Figure 3)[ 5]. Furthermore, 18 out of 32 cases received
surgeryasthesoletreatmentwithonlytworelapsecasesafter
24-month and 72-month followup (Table 1, Figure 2).
The 2010 National Comprehensive Cancer Network
(NCCN) GIST Guidelines state that the ﬁrst step in the
management of a potentially resectable GIST is to determine
its resectability with history/physical exam together with
tests such as computed tomography (CT) and/or magnetic
resonance imaging (MRI), chest imaging, endoscopic ultra-
sound (EUS), and endoscopy. PET scan is not routinely
recommended [5]. If the mentioned test did not show any
metastatic disease, preoperative biopsy of suspected GISTs is
usually not indicated (Figure 3); the NCCN recommends a
biopsy only if the tumor is unresectable, if the diagnosis in
doubt, or if neoadjuvant therapy is planned [5, 63].
Before the imatinib era, resected GISTs can have high
recurrence and failure rates with a 5-year survival of 28–35%
[62, 63]. Tumors of more than 10cm in size were associated
with 5-year disease-free survival (DFS) of only 20% and me-
dian times to progression (TTP) of seven months to two
years with only 10% of patients remained disease-free after
followup [63]. Although a recent population-based observa-
tional cohort study by Joensuu et al. concluded that most
patients with operable GISTs are cured by surgery alone with
60% estimated 15 years RFS, the study has a median tu-
mor diameter of 5.5cm with tumors mostly located in the
stomach [60]. This raises additional questions as to the exact
estimate of RFS, since the size and the location of the tumor
have a prognostic implication in risk stratiﬁcation.
7.2. Imatinib and Sunitinib. Imatinib mesylate and sunitinib
maleate are competitive inhibitors of KIT and PDGFRA [4,
10]. Both drugs bind and stabilize the inactivated form of the
receptor tyrosine kinases which leads to inhibition of phos-
phorylation and downstream KIT signaling activation. Its
limited ability to bind to inactivated form of the tyrosine
kinase is one of the reasons of drug resistance [10]. These
drugs also diﬀer on their binding targets. While Imatinib
bindstoaspeciﬁcaminoacidresiduewithintheATPbinding
pocket and the activation loop, Sunitinib interacts with a
structurally diﬀerent amino acid residue within the ATP
binding pocket [4].
The usual starting dose of Imatinib is 400mg per day.
Large trials on low-dose (400mg) versus high-dose (800mg)
Imatinib therapy showed the latter was associated with a
longer time to disease progression but did not improve over-
all survival with slightly improved progression-free survival
[1, 10]. However, a higher dose of imatinib was also asso-
ciated with a much higher rate of side eﬀects. Side eﬀects
of imatinib therapy include edema, muscle cramps, nausea,
vomiting, fatigue, and rash. Hematologic eﬀects include
anemia, neutropenia, and elevated liver function tests [1, 9].
Sunitinib, an inhibitor of KIT, PDGFRs, VEGFT 1, 23,
FLT3,andRET,wasapprovedasasecond-linetherapyforad-
vance GISTs after imatinib resistance and/or tolerance [4, 10,
64]. Sunitinib scheduled dosing consists of 50mg per day
for four weeks followed by a two-week rest period. Sunitinib
potentially inhibits double mutation of the ATP binding
pocket which is not possible with imatinib, but has little
activity against double mutation in the activation loop, mak-
ing it more potent against imatinib-resistant ATP binding
pocket mutation but inferior potency against the activation
loop [10]. Side eﬀects of sunitinib include fatigue, diarrhea,
skin discoloration, nausea, dysgeusia, stomatitis, vomiting,
hand foot syndrome, dyspepsia, dry mouth, and glossodynia
[65]. Most frequent hematologic side eﬀects in decreasing
order of frequency include leukopenia, neutropenia, anemia,
and thrombocytopenia [64].
7.2.1. Postoperative Imatinib. Interim results from ACOSOG
Z9001 phase III double-blind trial for KIT-positive GIST
showed improvement of RFS with imatinib treatment post-
operatively. ASCOG Z9001 stratiﬁed risk based only on
tumor size [5, 66]. Another study by de Matteo et al.ISRN Gastroenterology 11
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Figure 2: Summary of treatment options and relapse rate on 32 case reports.
on 713 patients who completed one year of postoperative
imatinib treatment showed a signiﬁcant improvement of
r e l a p s ef r e es u r v i v a l( R F S )b u tn o ti no v e r a l ls u r v i v a l( O S )
[1, 5]. Two large trials in Europe are investigating RFS in
postoperative imatinib treatment: the phase III trial EORTC/
GSF/GEIS/AGIT62024andthephaseIIIrandomized,multi-
center study SSGXVIII/AIO [5, 66].
Postoperative imatinib treatment is recommended if the
tumor is removed grossly, but the operative specimen has
positive microscopic margins, designated as R1 resection, or
if a gross visible tumor was left behind designated as R2
resection. Observation is all that is recommended if an R0
resection (negative microscopic margins) was achieved [5,
63]. The consensus at this time is to treat patient in a multi-
disciplinary approach based on biopsy margin, tumor size,
mitotic rate, site, immunohistochemical staining, and muta-
tional status [5, 63, 66, 67]( Figure 3).
7.2.2. Imatinib Resistance. Most GIST patients will achieve
the clinical beneﬁts with imatinib, but an estimated 10% will
progress within 3 to 6 months of initiating therapy. Such
cases are described as showing primary resistance to treat-
ment. Another 40% to 50% of patients will go on to
develop resistance within the ﬁrst two years [10]. In the cases
reviewed,1outof5GISTsinthestomachandthesmallintes-
tine developed resistance/relapsetoimatinib treatmentwith-
in two years (Table 2).
Primary imatinib resistance is observed in roughly 10%
of all genotypic subtypes of GIST. Most cases that show pri-
maryresistancearekit andPDGFRAwildtype,thosewithkit
exon9mutationsandthosewithPDGFRAD824V mutation.
Imatinib only binds to the inactive form of PDGFRA. Fur-
thermore,theD824VmutationofPDGFRAresultsinchange
in the kinase activation loop which favors active conforma-
tion, thereby making it resistant to imatinib. In patients who
do not harbor the PDGFRA or kit mutation, the mechanism
of resistance is potentially a mutation in another alternate
signaling pathway [10].
Delayed imatinib resistance is most often associated with
expression of tumor clones with secondary kit or PDGFRA
mutations. In phase II clinical trial of imatinib, 67% of
patients with delayed resistance had tumor clones with one
or more secondary kinase mutation. All secondary kit and
PDGFRA mutations were found on GIST with underlying
primary kit and primary PDGFRA mutation, respective-
ly. No secondary mutations were noted in samples after
imatinib that lacked a primary mutation, such as wild-type
GISTs. Kit mutation also shows mutational heterogeneity;12 ISRN Gastroenterology
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Figure 3: Schematic diagram on the stepwise approach to patients with GIST.
abiopsyofoneprogressinglesionmaynotbearepresentative
of others. Hence, making genotyping for resistance is more
diﬃcult and is not recommended for routine clinical man-
agement [10].
7.2.3. Sunitinib Resistance. The response to sunitinib corre-
lates closely with the tumor mutation status prior to ima-
tinib treatment. The median progression-free survival and
overall survival with sunitinib were signiﬁcantly longer for
patients with secondary kit m u t a t i o n si ne x o n1 3o r1 4
than those with secondary kit m u t a t i o n si ne x o n1 7o r
18. This correlates that sunitinib potentially inhibits the
phosphorylationofKITdoublemutationinATPbindingsite
but not in mutations of the activating loop. Sunitinib also
hasincreasedpotencyagainstimatinib-resistantATPbinding
pocket mutation but inferior potency against the activation
loop[10].Nocasereportofsunitinibresistancewasreported
in our review (Table 1, Figure 2).
8. FutureDirection
8.1. Monoclonal Antibodies. Newer monoclonal antibodies
are being developed for treatment of imitinib/sunitinib resis-
tance GISTs. These include nilotinib, sorafenib, dovitinib,
crenolanib, pazopanib, and dasatinib.ISRN Gastroenterology 13
Nilotinib (Tasigna) is an orally bioavailable aminopy-
rimidine-derivative Bcr-Abl tyrosine kinase inhibitor with
antineoplastic activity [68]. It is designed to overcome
imatinib resistance and is currently approved by the FDA for
the treatment of chronic lymphocytic leukemia. Preliminary
studies with nilotinib have shown that it can provide a
clinical beneﬁt in patients who have failed ﬁrst- and second-
line therapies by binding to KIT and PGDFRA. It is well
tolerated in patients with advanced GIST [68, 69]. Phase II
trials are underway to assess its eﬃcacy as third-line therapy.
The preliminary results from a recent phase III trial to inves-
tigate the eﬃcacy of nilotinib as ﬁrst-line treatments in pa-
tients without prior imatinib therapy are unlikely to demon-
stratesuperiorityoverthestandardofcare,whichisimatinib,
hence it was discontinued [67].
Dasatinib is structurally unrelated to imatinib, pos-
sibly demonstrating a higher aﬃnity to KIT. It inhibits
KIT autophosphorylation and KIT-dependent activation of
downstream pathways. Preclinical cell studies indicate that
dasatinib may inhibit the KIT D816V mutation that is resis-
tanttoimatinib[70].AstudybySchittenhelmetal.alsoindi-
cates a possible activity against KIT activation loop muta-
tions D816Y, D116F and D816V making it useful for ima-
tinib-resistant GISTs [70, 71] .Am u l t i c e n t e rp h a s eI It r i a l
sponsored by the Swiss Group for clinical research is testing
dasatinib as a ﬁrst-line treatment in gastrointestinal stromal
tumors (http://www.clinicaltrials.gov/).
Crenolanib (CP-868,596) developed by AROG Pharma-
ceuticals is an orally bioavailable small molecule targeting
the platelet-derived growth factor receptor (PDGFR), with
potential antineoplastic activity. Phase I and phase IB trials
are assessing its safety, tolerability, and pharmacokinetics
when combined with other drugs and chemotherapeutic
agents. Both trials demonstrated well tolerability with pro-
mising results [72, 73]. Crenolanib is undergoing phase II
trials for the treatment of GISTs with PDGFRA mutation,
whicharemostlikelyresistanttoimatinibandsunitinib[74].
Pazopanib (Votrient) is a small-molecule inhibitor of
multiple protein tyrosine kinases with potential antineoplas-
ticactivity.Pazopanibselectivelyinhibitsvascularendothelial
growth factor receptors (VEGFR)-1, -2, and -3, KIT, and
platelet derived growth factor receptor (PDGFR), which
inhibit angiogenesis in tumors were these receptors are
bound [75]. Pazopanib is FDA approved for renal cell
carcinoma treatment. It is undergoing clinical trial for
treatment of advanced solid tumors, including GISTs (http://
www.clinicaltrials.gov/).
Dovitinib (TKI258) is another KIT/PDGFRA inhibitor
and VEGF inhibitor developed by Novartis. Initial phase
I studies demonstrated well tolerability in 35 patients. Its
activityagainstthetyrosinekinasepostulateditspossibleeﬃ-
cacy against other solid tumors such as GIST. The most com-
mon side eﬀects with dovitinib include fatigue, nausea, vo-
miting, and diarrhea [76]. A phase II trial is on its way as
a third-line treatment for imitinib/sunitinib-resistant GIST
(http://www.clinicaltrials.gov/).
Sorafenib(BAY43-9006,Nexavar)isanoralmulti-kinase
inhibitor that blocks the RAF kinase and VEGF receptors 2
and 3 to target tumor cell growth and angiogenesis. It also
blocks PDGFR-B, KIT, FLT-3, and RET [77, 78]. Sorafenib
wasinitiallyapprovedbytheFDAforthetreatmentofkidney
cancer. Sorafenib is undergoing phase II trial as fourth-line
treatment in imatinib-, sunitinib-, and nilotinib-resistant
metastatic GIST (http://www.clinicaltrials.gov/).
8.2. HSP-90. Heat shock protein 90 (Hsp90) is an ATP-
dependentchaperoneprotein requiredforthe properfolding
and activation of other cellular proteins, particularly kinases
[79–81]. Hsp-90 interacts with more than 200 proteins;
many of these “client proteins” include AKT, BCR-ABL,
NPM-ALK, BRAF, KIT, MET, EGFR, FLT3, HER2, PDGFRA,
VEGFR, which are expressed in CML, CLL, lymphoma,
AML,non-small-celllungcancer,breastcancer,prostatecan-
cer, and GIST [80, 81]. It has been shown to be critical to
cancer cell growth, proliferation, and survival. They are the
new targets of clinically validated cancer drugs.
HSP-90 has a critical role in the maintenance of multiple
oncogenic pathways and is required to maintain the proper
folding, the stability, and the functionally active conforma-
tion of many aberrant oncoproteins [81]. Pharmacologic in-
hibitionofHSP-90bysmallmoleculesdestabilizesthecancer
cell protein leading to degradation by proteasomal enzymes
[80].
The ﬁrst Hsp90 inhibitor to enter clinical trials was the
geldanamycin (GM) derivative 17-allylamino-17-demeth-
oxygeldanamycin (17-AAG). HSP-90 inhibitors include the
two 17-AAG formulations, tanespimycin and IPI-504. Syn-
thetic HSP-90 inhibitors are also being developed, which
includes purine-scaﬀold Hsp90 inhibitor CNF2024/BIIB021,
the isoxazole derivative VER-52296/NVP-AUY922, and car-
bazol-4-one benzamide derivative SNX-5422 [80]. A third
type of Hsp90 is being developed by Synta Pharmaceuticals,
the STA 9090. It is an HSP-90 inhibitor unrelated to the an-
samycin family and is undergoing phase II clinical trial for
patients with GISTs [81]. Two phase II trials are underway
forAUY-933,theisoxazolederivativeof17-AAGintreatment
for refractory GISTs [80].
STA-9090 (ganetespib) is a novel second-generation, re-
sorcinol-containing triazole heat shock protein inhibitor
(HSP-90) that has shown the ability to inhibit multiple
kinases with comparable potency to, and a broader activity
proﬁle than, speciﬁc kinase inhibitors such as imatinib,
erlotinib, and sunitinib in preclinical trials. STA-9090 binds
to the ATP-binding pocket at the N-terminus of Hsp90
and acts as a potent Hsp90 inhibitor. STA-9090 has shown
potency10to100timesgreaterthanthegeldanamycinfamily
of Hsp90 inhibitors, as well as activity against a wider range
of kinases. In vivo models have shown strong eﬃcacy in a
wide range of cancer types, including cancers resistant to
Gleevec, Tarceva, and Sutent [81, 82]. Phase II trials are un-
derway to determine its eﬀectiveness in the treatment of
patients with metastatic and/or unresectable tumor that re-
ceived prior imatinib or sunitinib treatment [81].
9. Conclusion
GIST is a tumor with growing concern. Despite surgery
and neoadjuvant treatment, it remains a source of resistance14 ISRN Gastroenterology
with a devastating impact on mortality and healthcare. The
diagnosis of GIST is often delayed owing to its indolent
symptoms that only present in advance and sometimes
unresectablestage.Immunohistochemicalstainingisauseful
aid in diagnosing GISTs. Newer staining techniques, such as
the highly speciﬁc DOG1, sound promising in diagnosing
GIST and eventually would channel patients to its proper
treatment. AFIP is still the most commonly used risk stratiﬁ-
cation for prognosis and treatment, although its complexity
has raised questions on its usefulness. Newer methods of
staging using TNM system is available but needs further
validation on its role in predicting prognosis and treatment
outcome.
With the understanding of the molecular biology on
how GIST progresses together with the advancement of im-
munohistochemical staining, newer drugs are being devel-
oped that speciﬁcally target areas were tyrosine kinase and
PDGFRA are being activated. It has also revolutionized our
understanding of drug resistance and how to overcome such.
Surgery still remains as the primary mode of treatment
despiteahighincidenceofrecurrence,owingtothelackofal-
ternative treatment options. Improvement in surgical tech-
niqueshas decreasedtheincidence oftumorrecurrencefrom
tumor seeding. Postoperative imatinib treatment has also
shown to improve relapse-free survival (RFS) but not overall
survival (OS) and needs further studies which, at present,
are being done by 2 large clinical trials in Europe. With the
occurrence of imatinib and sunitinib resistance drugs, third-
and fourth-generation tyrosine kinase and PDGFRA inhi-
bitors are being developed and undergoing clinical trial that
would hopefully change the course of management of GISTs
in the very near future.
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